Articles By Jeffrey Sparks
RA-ILD in the Spotlight at ACR 2024
Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options. There is also a shocking lack of trial data. This year, there were two oral sessions dedicated to RA-ILD, one of which even the overflow room was standing room only, in addition to many posters.
Read ArticleRespiratory Burden of RA
Lung complications in RA remain a major issue, termed the “respiratory burden of RA.” Respiratory mortality is one of the leading causes of death for people with RA, particularly those with seropositive RA.
Read ArticleRheumatoid arthritis and lung disease in the spotlight at #ACR20
Rheumatoid arthritis (RA) has long been established to have pulmonary manifestations such as interstitial lung disease (ILD), and several research groups are pursuing this respiratory burden of RA at #ACR20.
Read ArticleAnswering questions on how COVID-19 affects rheumatic patients
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Read Article